References
- Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30(6):911–33
- Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30(5 Pt 1):677–98
- Elewski BE. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol 1995;32(3):500–1
- Brodell RT, Helms SE, Snelson ME. Office dermatologic testing: the KOH preparation. Am Fam Physician 1991; 43(6):2061–5
- Halasz CL. Successful treatment with fluconazole of tinea corporis caused by Trichophyton verrucosum (barn itch). Cutis 1994;54(3):207–8
- Roberts SO. Pityriasis versicolor: a clinical and mycological investigation. Br J Dermatol 1969;81 (5):315–26
- Faergemann J, Fredriksson T. Tinea versicolor: some new aspects on etiology, pathogenesis, and treatment. Int J Dermatol 1982 Jan-Feb;21(1):8–11
- Faergemann J, Fredriksson T. Age incidence of Pityrosporum orbiculare on human skin. Acta Derm Venereol 1980; 60(6):531–3
- Martin AG, Kobayashi GS. “Pityrosporum infections” of the skin: papulosquamous tinea versicolor, “Pityrosporum” folliculitis, and inverse tinea versicolor. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in general medicine. Vol 2. 4th ed. New York: McGraw-Hill, 1993:2462–7
- Guidelines/Outcomes Committee of the American Academy of Dermatology. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. J Am Acad Dermatol 1996; 34(2 Pt 1):287–9
- Schwartz RA, Janniger CK. Tinea capitis. Cutis 1995;55(1):29–33
- Elewski BE. Tinea capitis: itraconazole in Trichophyton tonsurans infection. J Am Acad Dermatol 1994;31 (1):65–7
- Kelley L, Howard R, Frieden IJ. Tinea capitis: diagnosis and treatment. Fitzpatrick's J Clin Dermatol 1994;Jul/Aug: 43–6
- Ginsburg CM, McCracken GH Jr, Petruska M, et al. Effect of feeding on bioavailability of griseofulvin in children. J Pediatr 1983; 102 (2):309–11
- Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J Am Acad Dermatol 1989;21 (6): 1209–12
- Guidelines/Outcomes Committee of the American Academy of Dermatology. Guidelines of care for superficial mycotic infections of the skin: Onychomycosis. J Am Acad Dermatol 1996;34:116–21
- Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131 (8):937–42
- Kuokkanan K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3:115–7
- Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993;29(1): S45–50
- Hochman LG, Scher RK, Meyerson MS, et al. The safety and efficacy of oral fluconazole in the treatment of onychomycosis. J Geriatr Dermatol 1993;1(4):169–72
- Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed- an investigation in onychomycosis. Clin Exp Dermatol 1991; 16(5):374–6
- De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132(1):34–41
- Kates SG, Nordstrom KM, McGinley KJ. Microbial ecology of interdigital infections of toe web spaces. J Am Acad Dermatol 1990;22(4):578–82
- Brodell JD, Brodell RT. Recurrent lymphangitic cellulitis syndrome. Contemp Orthopaed 1992;25(5):461–8
- Leyden JJ. Progression of interdigital infections from simplex to complex. J Am Acad Dermatol 1993;28(5 Pt 1):S7–11
- Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995;33:259–60
- Brodell RT, Elewski BE. Systemic antifungal drugs and drug interactions. (Letter) J Am Acad Dermatol 1995;35(1): 135
- Grevelink S, Fitzpatrick TB. Drug interactions. I. Antifungals. Fitzpatrick's J Clin Dermatol 1994;Nov/Dec:57
- Martin AG, Kobayashi GS. Tinea cruris. In: Fitzpatrick, et al, eds,' pp 2436–7